Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Bevacizumab for Second Eye NAION
NCT00813059Phase 2Unknown
- Sponsor
- Mount Sinai Hospital
- Start
- Feb 2009
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by Mount Sinai Hospital. Primary endpoint: Percentage of patients who gained three or more lines of vision at 6 months. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT00813059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813059.